Hyperfractionated Accelerated Radiotherapy (HART) With Chemotherapy (Cisplatin, CCNU, Vincristine) for Metastatic (M1-3) Medulloblastoma
- Determine the toxicity of hyperfractionated accelerated radiotherapy (HART) in young
patients with metastatic medulloblastoma.
- Determine the toxicity of chemotherapy (vincristine during radiotherapy and 8 courses
of lomustine, cisplatin, and vincristine after radiotherapy) in association with HART
in these patients.
OUTLINE: This is a multicenter study.
- Radiotherapy and vincristine: Beginning 4-6 weeks after surgery, patients undergo
hyperfractionated accelerated radiotherapy (HART) twice a day, 5 days a week, for 5
weeks. Patients also receive vincristine IV once weekly for 8 weeks beginning in week
1*. Approximately 6-8 weeks after completion of radiotherapy, patients proceed to
NOTE: *The first 7 patients undergo radiotherapy without receiving vincristine
- Maintenance chemotherapy: Patients receive oral lomustine once on day 1 and cisplatin
IV over 6 hours on day 1 and vincristine IV on days 1, 8, and 15. Treatment repeats
every 6 weeks for 8 courses in the absence of disease progression or unacceptable
After completion of study treatment, patients are followed periodically for 5 years.
PROJECTED ACCRUAL: A total of 29 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Roger Taylor, MD
United States: Federal Government